Banque Transatlantique SA Invests $411,000 in Novo Nordisk A/S (NYSE:NVO)

Banque Transatlantique SA purchased a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,810 shares of the company's stock, valued at approximately $411,000.

Several other hedge funds also recently made changes to their positions in the stock. Victory Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after acquiring an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC raised its position in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after buying an additional 30,420 shares in the last quarter. Versant Capital Management Inc bought a new position in Novo Nordisk A/S in the 4th quarter worth about $86,000. Finally, Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $4,066,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research reports. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Stock Down 4.0 %

NVO traded down $2.80 on Tuesday, hitting $66.32. The company had a trading volume of 10,488,030 shares, compared to its average volume of 6,255,246. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The stock has a fifty day simple moving average of $71.06 and a 200-day simple moving average of $87.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $297.63 billion, a P/E ratio of 20.16, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a dividend of $0.7874 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.